Study: Colorectal Cancer Screenings Increase When Patients Given Options

Share on Facebook

A new study published in the Archives of Internal Medicine reveals patients are more likely to undergo colorectal cancer screening if they are provided choices for the type of screening test, according to a news release.

 

The study was conducted by John M. Inadomi, MD, of the University of Washington School of Medicine, Seattle, and colleagues. They enrolled 997 participants in a randomized clinical trial conducted in the San Francisco Community Health Network, the public healthcare system of San Francisco.

 

Within 12 months of enrollment, 58 percent completed the colorectal cancer screening strategy they were assigned or chose. However, a significantly lower percentage of participants (38 percent) in the colonoscopy group completed that procedure compared with participants in the fecal occult blood testing group completing that screening (67 percent) or those participants who were allowed to choose their screening (69 percent).

 

"This study found that limiting the recommendation for colorectal cancer screening to colonoscopy can result in a lower completion rate for colorectal cancer screening compared with providing a choice between FOBT or colonoscopy, especially among ethnic/racial minorities," the authors commented, according to the release.

 

The authors also observed significant racial/ethnic differences in screening completion, with whites more often completing colonoscopy and nonwhites more often completing FOBT.

 

Related Articles on Colorectal Cancer Screening:

Which Procedures Do Surgery Centers Perform Most? 40 Statistics on 4 Common Specialties

Gastroenterologist Dr. Kevin Behrle Writes Column on Colorectal Cancer Screening for Local Publication

Gastroenterologist Dr. Kenneth Shieh Discusses Colorectal Cancer in Local Publication

© Copyright ASC COMMUNICATIONS 2014. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New From Becker's GI & Endoscopy

FDA approves gastroenteropancreatic neuroendocrine tumor drug

Read Now